SAI PARENTERALS LIMITED
NSE: SAIPARENTMarket Closed • NSE
Day range
52 week range
SAI PARENTERALS LIMITED closed at INR493.90 (-1.31%) on volume 1.48x its 20-day average, trading 30.04% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved -39.8% QoQ
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.49x
High Cash Flow Conversion: CFO/PAT averaged 3.34x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 177.0x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - General.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.92 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.48L | 84.75 | 0.32% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.77L | 74.39 | 0.82% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.17L | 183.15 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.15L | 55.26 | 0.26% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.11L | 24.91 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.10L | 100.67 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.05L | 31.20 | 0.99% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.[1]
IndiaHealthcare
Is SAI PARENTERALS LIMITED Shariah compliant?
SAI PARENTERALS LIMITED is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (21.49%) complies with AAOIFI threshold (≤ 33%).
What is SAI PARENTERALS LIMITED's current valuation relative to peers?
SAI PARENTERALS LIMITED trades at a P/E of 177.0x compared to the sector median of 37.6x, and a Price-to-Book of 3.3x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.49x and a Net Debt to EBITDA ratio of 12.03x. Interest coverage is 2.1x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 31.5% while net profit growth averaged 28.5%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.